Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Remo Moomiaie-Qajar M.D.
AddedMar 31, 2024
UpdatedMay 31, 2026
Remo Moomiaie-Qajar M.D.

Remo Moomiaie-Qajar M.D.

Co-Founder & CEO, Cytonus Therapeutics

CrunchbaseLinkedIn

Remo Moomiaie-Qajar M.D.'s Career

Cytonus Therapeutics
Cytonus Therapeutics

Carlsbad, CA, US

Co-Founder & CEO· C-Suite · Management
Zerigo Health
Zerigo Health

San Diego, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Remo Moomiaie-Qajar M.D.'s Career

Cytonus Therapeutics
Cytonus Therapeutics
Series A$18.9M132018Carlsbad, CA, US
Co-Founder & CEO· C-Suite · Management

Leadership at Cytonus Therapeutics

Richard KlemkeRichard KlemkeCo-Founder

Similar to Cytonus Therapeutics

CytodelCytodelNew York City, NY, USBiopharmaceuticalsest. 2012CytodelNew York City, NY, US · est. 2012

Cytodel, Inc., a NY-based biopharmaceutical firm, produces recombinant botulinum neurotoxin derivatives.

Series A · $225k5
ZY TherapeuticsZY TherapeuticsCary, NC, USDrug Deliveryest. 2015ZY TherapeuticsCary, NC, US · est. 2015

ZY Therapeutics: Pioneering nanotech-based drug delivery platforms for cancer treatment.

Series A · $6M11
Carigent TherapeuticsCarigent TherapeuticsNew Haven, CT, USDrug Deliveryest. 2006Carigent TherapeuticsNew Haven, CT, US · est. 2006

Innovative biotech firm with advanced drug delivery solutions.

Series A · $2M5
CargeneCargeneCambridge, MA, USDrug Development, Therapeuticsest. 2020CargeneCambridge, MA, US · est. 2020

Cargene: A bio-pharmaceutical firm innovating oligonucleotide therapies for cardiovascular and lung diseases.

Seed · $19.2M26
Zerigo Health
Zerigo Health
Series B$67.4M422014San Diego, CA, US
Co-Founder

Leadership at Zerigo Health

Robert GarberRobert GarberBoard Member
Lisa RomettyLisa RomettyCEO
Martyn GrossMartyn GrossCo-Founder
Glen TullmanGlen TullmanBoard Member

Similar to Zerigo Health

Luma TherapeuticsLuma TherapeuticsMillbrae, CA, USMedical Devicesest. 2016Luma TherapeuticsMillbrae, CA, US · est. 2016

Luma Therapeutics: Innovating light therapies for inflammatory skin diseases, specializing in psoriasis.

Seed · $2M7
Noctrix HealthNoctrix HealthPleasanton, CA, USMedical Devicesest. 2018Noctrix HealthPleasanton, CA, US · est. 2018

Noctrix Health: An innovative medical device company developing revolutionary therapy for chronic illnesses.

Series C · $57M37
Zeus HealthZeus HealthMenlo Park, CA, USMedical DevicesZeus HealthMenlo Park, CA, US

Innovative medical device manufacturer in Menlo Park, CA.

6
Presidium HealthPresidium HealthSan Diego, CA, USHealthcareest. 2015Presidium HealthSan Diego, CA, US · est. 2015

Presidium Health: San Diego-based mobile healthcare provider offering 24/7 home-based medical services.

Series A · $9.7M125

Remo Moomiaie-Qajar M.D.'s Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Remo Moomiaie-Qajar M.D.

Juan EnriquezJuan EnriquezFounder & CEO · BiotechonomyJeffrey AbbottJeffrey AbbottBoard Member · CytoTronicsLawrence TamarkinLawrence TamarkinCo-Founder · CytImmune SciencesAjay ShahAjay ShahCEO · CytovaleGaetano ScuderiGaetano ScuderiBoard Member · Cytonics